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The major antimalarial drug quinine perturbs uptake of the essential amino acid tryptophan, and patients
with low plasma tryptophan are predisposed to adverse quinine reactions; symptoms of which are similar to
indications of tryptophan depletion. As tryptophan is a precursor of the neurotransmitter serotonin (5-HT),
here we test the hypothesis that quinine disrupts serotonin function. Quinine inhibited serotonin-induced
proliferation of yeast as well as human (SHSY5Y) cells. One possible cause of this effect is through inhibition
of 5-HT receptor activation by quinine, as we observed here. Furthermore, cells exhibited marked decreases
in serotonin production during incubation with quinine. By assaying activity and kinetics of the
rate-limiting enzyme for serotonin biosynthesis, tryptophan hydroxylase (TPH2), we showed that quinine
competitively inhibits TPH2 in the presence of the substrate tryptophan. The study shows that quinine
disrupts both serotonin biosynthesis and function, giving important new insight to the action of quinine on
mammalian cells.
Q
uinine (QN) has been amainstay drug in the battle against malaria, which is responsible for the loss of up
to onemillion human lives each year1. However, QN efficacy as an antimalarial has been limited by some
incidence of drug resistance2 and by common adverse reactions among patients3,4. Adverse reactions also
impact the application of quinine as a treatment for leg cramps. The basis for these adverse reactions is poorly
understood, but recent research has shed some new light on the issue. Studies using a model organism, the yeast
Saccharomyces cerevisiae, revealed that transport of the essential amino acid tryptophan is inhibited by QN5. As a
result, QN causes tryptophan starvation, a toxic mode of action that can be suppressed in media with high
tryptophan5,6. The relevance of these findings to humans has been highlighted in clinical screens of malaria
patients treated with QN7. This demonstrated that patients with lower plasma tryptophan were more likely to
experience adverse reactions to QN, undermining its safety profile. This is important as tryptophan levels in
humans vary considerably between individuals8,9. Such differences are at least partly due to diet and, therefore,
dietary supplements could offer a simple way to manipulate QN responses in patients7.
This inter-relationship between QN and tryptophan resonates with an overlap in certain symptoms of trypto-
phan depletion and adverse QN reactions (cinochonism) in humans, such as tinnitus, anxiety and sleep disturb-
ance8–12. The fact that neuropsychological effects are among these overlapping contra-indications is notable, as
tryptophan is a metabolic precursor for the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Indeed,
tryptophan depletion results in decreased serotonin production13 and can trigger depression in susceptible
individuals as discussed below.
The dysregulation of themonoamine serotonin in the brain has been extensively studied and has been linked to
many psychiatric disorders14. Neuropsychological indications such as weakened decision making, poor mood or
sleep, pain, appetite and depression have all been linked to serotonin function14–16. Serotonin in organisms is
synthesised from tryptophan through two enzymatic reactions. The rate limiting reaction is catalysed by trypto-
phan hydroxylase (TPH), which converts tryptophan to the intermediate 5-hydroxytryptophan. Tryptophan
hydroxylase-2 (TPH2) performs this function in the central nervous system, while another isoform, TPH1, does
so in the periphery. Serotonin is subsequently produced from 5-hydroxytryptophan by aromatic amino acid
decarboxylase. Serotonin production is dependent on tryptophan availability, which hinges partly on tryptophan
transport across the blood-brain barrier17. Tryptophan is transported into the brain by the large neutral amino
acid (LNAA) transporter, in competition with several other amino acids. Such interactions make tryptophan
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metabolism difficult to predict. However, perturbation of tryptophan
availability has the potential to disrupt normal neuropsychological
performance. For example, acute tryptophan depletion in patients
with a history of depression and panic disorders can cause relapse of
the disorder18. Tryptophan deficiency is common in malnourished
populations in Africa, where QN is still routinely used as a treatment
for severe malaria.
As QN affects tryptophan availability and patients with low tryp-
tophan appear predisposed to adverse quinine reactions5,7, here we
hypothesize that such adverse effects of the drug could reflect per-
turbation of serotonin function. It has been noted previously thatQN
interacts at 5-HT3 receptors19,20. We exploit the yeast model in con-
junction with mammalian cells and biochemical assays to show that
QN can inhibit both serotonin production and function.
Results
Quinine inhibits stimulation of yeast growth by serotonin.
Previously it was shown that QN and tryptophan compete for
uptake in yeast5, and elsewhere that the tryptophan derivative
serotonin can stimulate yeast growth21. We exploited these insights
in some preliminary tests for interference of serotonin action by QN,
using the yeasts C. albicans and S. cerevisiae. The growth yield for C.
albicans and S. cerevisiae was increased significantly in the presence
of 1 mM serotonin, by 1.7-fold and 1.4-fold respectively (t-test, p,
0.0001 in both organisms) (Fig. 1). This indication of growth
stimulation by serotonin was partly suppressed by the inclusion of
1 mM QN in the medium (t-test, p 5 0.0017 and 0.0043 in C.
albicans and S. cerevisiae, respectively). When supplied alone QN
had no inhibitory effect on yeast growth at this concentration, as also
reported previously5. Therefore, QN specifically blocked serotonin-
stimulated growth.
Quinine inhibits human type 2 serotonin-receptor activation. It
was hypothesized that the inhibition by QN of serotonin action on
yeast growth might reflect an interaction between these structurally-
related molecules at one or more cell receptors. Previously, QN was
found to block activation of heterologously-expressedmammalian 5-
HT3 receptors19,20. To support and extend that finding, here the effect
of QN was tested in a human neuroblastoma cell line (SHSY5Y)
which expresses 5-HT2a/2c receptors, by measuring the level of
cellular calcium release in response to serotonin addition. Calcium
release (traced with the FLUO-4 probe) was markedly stimulated by
1 mM serotonin (Fig. 2). The known potent 5-HT2 receptor
antagonist, ketanserin, was used as a positive control. Ketanserin
effectively blocked calcium release by serotonin addition (Fig. 2).
At a concentration equimolar with serotonin, QN had negligible
effect on receptor activation. However, at 20 mM QN, the response
to serotonin was decreased by,30% (t-test, p5 0.015) and there was
no discernible response to serotonin in the presence of 200 mMQN.
Quinine inhibits stimulation of neuroblastoma cell growth by
serotonin. Having corroborated that QN interferes with serotonin
receptors on mammalian cells, we sought to test whether the
observed inhibition of serotonin-stimulated growth of yeast cells
(Fig. 1) was also apparent in mammalian cells. Previously, low
concentrations of serotonin have been reported to promote growth
of tumorigenic human cells lines22. In the present work, it was found
that 1 mM serotonin stimulated SHSY5Y cell proliferation by,14%
(t-test, p 5 0.016) (Fig. 3). The inclusion of 0.1 mM ketanserin
blocked this effect of serotonin. Similarly, and as in yeast, the
presence of QN (10 mM) reversed the growth stimulatory effect of
serotonin (Fig. 3). Neither 0.1 mM ketanserin nor 10 mM QN
affected cell proliferation when supplied alone.
Quinine inhibits serotonin production. Having established that
QN interferes with certain serotonin functions (above), we
hypothesized that the antimalarial may also perturb serotonin bio-
synthesis as the pathway commences with tryptophan, with which
QN competes5. Serotonin production was investigated first in yeast
cells transformed with pYES-TDC. This plasmid harbours a trypto-
phan decarboxylase gene from rice, which produces serotonin from
endogenous 5-hydroxy-tryptophan in yeast, so providing a yeast
model for serotonin biosynthesis23. Determination of serotonin
levels in the yeast cells by HPLC-ED showed that serotonin
production was decreased significantly when cells were cultured in
the presence of 2 mM (t-test, p 5 0.0082) or 4 mM (p 5 0.0069) QN
(Fig. 4a). These concentrations were sub-inhibitory and mildly
inhibitory to growth, respectively, but there was a $ 90% decrease
in serotonin production in both cases.
The effect ofQNon serotonin production was subsequently exam-
ined in the rat raphe RN46A cell line, which expresses TPH2 activity
and naturally produces serotonin. As a positive control, the known
TPH2 inhibitor, p-chlorophenylalanine (pCPA), was shown to
decrease serotonin levels significantly at pCPA concentrations
greater than 10 mM (Fig. 4b). In the case of QN, there was a decrease
in cellular serotonin production with increased QN concentration.
RN46A cells treated with 2 mM QN exhibited significantly lower
serotonin levels, at 65% of the amounts determined in control cells
(Fig. 4c). There was some growth inhibition of the RN46A cells at this
QN concentration, but this was normalized by expressing serotonin
amounts on a per cell basis.
High levels of quinine uptake by RN46A cells are not affected by
tryptophan supply. As QN inhibited serotonin production more
strongly in yeast than in the rat RN46A cells (Fig. 4), we hypo-
thesized that the yeast cells may take up more QN. To test this,
[9-3H]-QN uptake was compared in the two cell types. Contrary to
the hypothesis, QN uptake wasmuch greater in the RN46A cells than
in yeast (t-test, p 5 0.006) (Fig. 5a). To explore QN uptake further in
Figure 1 | Quinine inhibits stimulation of yeast growth by serotonin. C.
albicans SC5314 (upper panel) or S. cerevisiae BY4743 (lower) were
cultured in unsupplemented Sabouraud’s medium (#) or medium
supplemented with 1 mM serotonin (.), or 1 mM serotonin 1 1 mM
QN (&). (This concentration of QN has no inhibitory effect on yeast
growth when supplied alone5). Points are means from three independent
experiments. SEMs were smaller than the dimensions of the symbols.
www.nature.com/scientificreports
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the rat cell line, the effect of excess tryptophan was measured. In
contrast to previous work with yeast5, tryptophan addition did not
affect QN uptake by RN46A cells (Fig. 5b) suggesting a distinct
transport mechanism for QN in the rat cells.
Quinine competitively inhibits tryptophan hydroxylase 2. As the
impact of QN on serotonin production is influenced by cell type
(Fig. 4), and presumably also by in vitro experimental conditions
for cells, we tested the action of QN directly on the main rate-
limiting enzyme for serotonin biosynthesis, tryptophan hydroxylase
2 (TPH2). TPH2 catalyzes the synthesis of 5-hydroxytryptophan
from tryptophan. The activity of the purified catalytic domain of
human TPH224 was assayed over a range of tryptophan (substrate)
concentrations in the absence or presence of QN or pCPA. The
data conformed to Michaelis–Menten kinetics, and revealed that
increasing the concentration of QN from 0 mM to 2 mM then to
10 mM progressively decreased the TPH2 activity (Fig. 6a). Lin-
earisation of the data to produce Lineweaver-Burk plots indicated
that QN competitively inhibited TPH2 activity (as it was the
intercept with the x axis (21/Km) that was primarily affected by QN
concentration). A similar outcome was obtained for the competitive-
inhibitor of TPH2, pCPA, as a positive control (Supplementary Fig.
S1a). The data indicate that, like pCPA, QN competes with
tryptophan for binding to the active site of TPH2. The effects of
QN and pCPA were also assayed over varying concentrations of a
co-factor required for TPH2 activity, 6-methyltetrahydropterin
(6MePH4). In this case, and in contrast to the interaction with
tryptophan, altering the QN or pCPA concentrations gave non-
competitive inhibition of (6MePH4-dependent) TPH2 activity
(Fig. 6b and Supplementary Fig. S1b). This result was consistent
with the role of 6MePH4 as the enzyme co-factor, and reinforced
the distinctive competitive nature of the interaction between QN and
the substrate tryptophan.
Discussion
The key novel findings in this paper are that the antimalarial drug
quinine can interfere with both production and function of themajor
neurotransmitter serotonin. This could help to explain certain
adverse reactions to QN treatment seen among malaria patients,
particularly those with low dietary tryptophan3,4,7. The results also
raise the possibility that quinine could find application as an antidote
against serotonin syndrome, a condition linked to excessive sero-
tonin in patients25. As discussed below, the effect of QN on serotonin
production could be attributable to competition between the drug
and tryptophan (the substrate for serotonin biosynthesis) at two
principal sites: the active site of the rate-limiting enzyme for sero-
tonin biosynthesis (TPH), and transporters responsible for trypto-
phan uptake by cells.
To assay potential interactions between QN and serotonin
function, we exploited previous reports of serotonin-induced cell
proliferation in yeast and tumorigenic cells21,22,26,27, as well as the
availability of 5-HT2a,2c receptor-expressing cells. Aromatic alcohols
act as autoinducers of yeast and tumorigenic cell growth. In nitrogen
deficient media, tryptophol, an amino alcohol and tryptophan deriv-
ative is synthesized to autoinduce cell proliferation21. Because of the
structural similarity between serotonin and tryptophol, serotonin
can act as an autoinducer under the same conditions21. In the present
study, QN suppressed these proliferative effects of serotonin. Amine
Figure 2 | Quinine inhibits 5-HT2 receptor activation. Stimulation of calcium release from SHSY5Y cells by 1 mM serotonin addition was tested
in the absence or presence of ketanserin or quinine at the indication concentrations. Mean data are shown from three independent experiments. AU,
arbitrary units.
Figure 3 | Quinine inhibits stimulation of neuroblastoma cell growth by
serotonin. SHSY5Y cells were cultured in the absence (%) or presence (&)
of 1 mM serotonin, with ketanserin or quinine supplied at the indicated
concentrations where specified. Cell density was determined after 72 h
incubation. Mean data 6 SEM are shown from three independent
experiments.
www.nature.com/scientificreports
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alcohol receptors of yeast are poorly understood. In contrast, 5-HT
receptors are well described in higher cells, including as therapeutic
targets, and previous work indicated that QN inhibits activation of
mammalian 5-HT3 receptors expressed in Xenopus oocytes or HEK-
293 cells19,20. In addition, QN has been reported to inhibit active
serotonin uptake into rat synaptosomes28 and to affect serotonin-
modulated K1-channels29. Here, QNwas observed to inhibit calcium
signalling at 5-HT2a/2c receptors. This is important as 5-HT2
receptors are linked to a variety of neuropsychological disorders such
as anxiety and mood lowering effects16.
In mammals, serotonin production in the central nervous sys-
tem is rate-limited by the TPH2 enzyme30. The present in vitro
assays suggested that QN competes directly with tryptophan for
binding to the active site of TPH2, similar to the known compet-
itive TPH2 inhibitor, pCPA31. pCPA potently decreases serotonin
production in the brain31. The inference that QN, similarly, may
have the potential to suppress serotonin production by cells was
borne out by analysis of serotonin levels in RN46A cells and, in
particular, yeast cells. The strong effect in yeast cells was despite
relatively low levels of QN uptake (Fig. 5a), highlighting the poten-
tial potency of QN action in inhibiting serotonin production.
However, there was a smaller relative effect on serotonin produc-
tion in the rat serotonergic cell line RN46A, despite much higher
QN uptake. This indicates that the absolute intracellular QN level
is not the sole factor that determines inhibition of serotonin pro-
duction. We propose that another key factor involved here could
be cellular tryptophan concentration. Previously we showed that
QN and tryptophan compete for uptake via the Tat2p transporter
in yeast, leading to tryptophan depletion5. The high level of QN
uptake in RN46A cells appears to be through a different type of
mechanism, as excess tryptophan did not affect QN uptake. This
apparent lack of competition for uptake between tryptophan and
QN suggests that QN is unlikely to cause the cellular tryptophan
depletion in RN46A that occurs in yeast cells. Therefore, the lesser
impact of cellular QN on serotonin production in RN46A cells
may at least partly be attributable to relatively high tryptophan
levels in these cells, as this would balance the competition for
TPH2 binding in favour of the tryptophan substrate (Fig. 6a).
It is evident from the above discussion that the level of competition
with tryptophan both for uptake into cells and for TPH2 bindingmay
determine the relative impact of QN on serotonin production.
Competition at the point of uptake, in particular, is likely to vary
considerably: between cell types as seen here (e.g. depending on the
transporters expressed by cells), and between in vivo physiological
environments, as affected by interactions between cells, neurotrans-
mitters and hormones as well as organ type. For example, the level of
QN within the brains of patients is thought to be lower than in
peripheral tissues due to the blood-brain barrier32. Such considera-
tions may mitigate the fact that the effective QN concentrations used
in certain of our in vitro experiments with the RN46A cells were
higher than the recommended therapeutic dose, approaching QN
concentrations that are toxic to mammalian cells. More to the point,
the physiological relevance of interactions between QN and trypto-
phan has already been established in clinical studies, which provided
evidence for competition between these molecules in vivo and
showed that high plasma tryptophan decreases the incidence of
adverse reactions to therapeutic doses of QN in malaria patients7.
The present work shows how effects of QN on synthesis and function
of the major tryptophan metabolite, serotonin, provides a potential
explanation for such previous findings. This rationale has further
indirect support, from the similarities in the reported adverse neuro-
psychological effects of QN and of serotonin imbalance, which
include tinnitus, loss of appetite, sleep disturbance and anxi-
ety3,4,12,15,16. These issues underscore how adherence to the narrow
therapeutic index of QN during treatment may avert neurological
toxicity and serious adverse effects. Even then, however, several of
the effects we report (e.g., Figs. 2, 3, 5) did occur at quinine concen-
trations that are within the 4–100 mM ranges seen in human organs
or plasma during quinine treatment5,7. The present work also leaves
open the possibility that there are interactions between QN and
tryptophan at cellular sites additional to those studied to date, which
may have in vivo consequences beyond those suggested. For example,
tryptophan is also a precursor in the kynurenine pathway, which is
known to play a role in cerebral malaria33,34. A high level of QN
Figure 4 | Quinine inhibits serotonin production. (A) Yeast cells
transformed with pYES-TDC were cultured for 24 h in the presence of the
indicated quinine concentration before determination of cellular
serotonin with HPLC-ED. (B) Serotonin was determined in rat RN46A
cells after 5 d culturing with the indicated concentration of the TPH2
inhibitor, pCPA. (C) Serotonin was determined in rat RN46A cells after
5 d culturing with the indicated concentration of quinine. Mean values are
shown 6 SEM from three independent experiments.
www.nature.com/scientificreports
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uptake by mammalian cells, indicated here, may underpin many
effects of this drug.
Methods
Yeast growth. The yeast strains Saccharomyces cerevisiae BY4743 or Candida
albicans SC5314 were cultured in Sabouraud’s medium containing 30 g L21 maltose,
10 g L21 peptone from casein (Sigma), 3 g L21 yeast extract (Sigma), adjusted to pH
7.021. After 24 h growth of starter-cultures, strains were inoculated to the same
medium in Erlenmeyer flasks and incubated for 4 h at 34uC with orbital shaking at
120 rev min21. Cultures were then adjusted to 106 cells mL21 in the same medium
and distributed in 300 mL aliquots per well in 48-well plates (Greiner Bio-One).Wells
were supplemented with serotonin hydrochloride (Sigma) or quinine
dihydrochloride dihydrate (QN; Sigma) as specified. Growth of the yeasts with
shaking at 34uC was monitored with a BioTek Power Wave XS2 Microplate
Spectrophotometer.
Mammalian cell culture.Human neuroblastoma SHSY5Y cells (a gift from Professor
David Kendall, University of Nottingham) and rat raphe RN46A cells (a gift from Dr
Scott Whittemore, University of Louisville) were cultured in DMEM-F12 HAM
nutrient medium (Sigma) supplemented with 10% (v/v) fetal calf serum (Sigma),
2 mM L-glutamine, 100 U mL21 penicillin and 100 mg mL21 streptomycin35. Cells
were cultured in 25 cm2 cell culture flasks in 5 mLDMEM-F12medium at 36.5uC, 5%
CO2 until confluent. Cells were detached from the bases of flasks with 2 mL trypsin-
EDTA solution (Sigma). DMEM-F12 medium (10 mL) was added to the flask,
followed by 7 min centrifugation at 600 g. The cell pellet was resuspended in 10 mL
Figure 5 | Quinine uptake by yeast and rat RN46A cells. (A) Yeast (transformed with pYES-TDC) or RN46A cells were incubated in the presence of
100 mMquinine supplemented with 0.9 mCiml21 [3H]-quinine. Cellular radiolabel uptake was determined after 24 h for yeast or 5 d for RN46A cells (i.e.
the same intervals as for serotonin determination, Fig. 4) and the derived scintillation counts normalized to cellular protein. (B) As in (A) for RN46A cells,
but with additional parallel incubations in the presence of 1 mM L-tryptophan. All values are means 6 SEM from three independent experiments.
Figure 6 | Effect of quinine on in vitro TPH2 activity. (A) Initial rate of activity of the purified catalytic domain of human TPH2 (v) was assayed in the
presence of 0 (#), 2 (.) or 10 (%) mM QN at different concentrations of the L-tryptophan substrate [S]. Points are means from three replicate
determinations of v. SEMs were smaller than the dimensions of the symbols. The data are presented as substrate saturation curves (left panel) and
Lineweaver-Burk plots (right). (B) As in (A) but where [S] refers to different concentrations of the TPH2 co-factor 6MePH4.
www.nature.com/scientificreports
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DMEM-F12. An aliquot (0.5 mL) of the cell suspension was added to 4.5 mL
DMEM-F12 in 25 cm2 cell culture flasks, and cultured until confluent at 36.5uC in 5%
CO2.
Mammalian cell proliferation. The assay was adapted from that described
previously22. From confluent cultures (above), SHSY5Y cells were adjusted to 5 3
105 cells mL21 inDMEM-F12medium and 100 mL aliquots seeded to individual wells
of flat-bottomed 96-well plates. Wells were supplemented with serotonin, ketanserin
(a selective 5-HT2 receptor antagonist, Sigma) or QN as specified in the results
section. Plates were incubated at 36.5uC, 5% CO2 for 72 h, before cells were detached
by addition of 50 mL trypsin-EDTA solution. Detached cell mixture was added to
200 mL freshmedium inmicrocentrifuge tubes. Cells were centrifuged (600 g, 7 min)
and the supernatant removed by aspiration. Cells were resuspended in 100 mL fresh
medium and counted using a Neubauer hemocytometer (1/400 square mm, depth
0.1 mm).
Serotonin receptor activity. SHSY5Y cells were cultured in clear-bottomed 96-well
black plates (Cellstar) for 48 h in DMEM-F12 at 36.5uC, 5% CO2. The medium was
then aspirated and 200 mL of DMEM-F12, 10% (v/v) fetal calf serum, containing
100 U mL21 penicillin, 100 mg mL21 streptomycin, 1 mM FLUO-4 (Invitrogen) and
2.5 mM probenecid (Sigma), were aliquoted to each well. After 45 min incubation at
30uC, 5%CO2, cells were washedwithHEPES buffered saline (10 mMHEPES, 2 mM
sodium pyruvate, 10 mM D-glucose, 0.145 M sodium chloride, 1 mM magnesium
sulphate, 5 mM potassium chloride, 1.3 mM calcium chloride, 1.5 mM sodium
hydrogen carbonate, pH 7.45) containing 2.5 mMprobenecid. Following this, 180 mL
of HEPES buffered saline containing 2.5 mM probenecid were added to each well.
Where specified, the saline was supplemented with ketanserin or QN. After
incubation of plates on a hot plate at 30uC for 20 min, the cells were examined with a
FlexStation3 Microplate Reader (Molecular Devices) using SoftMaxH Pro software,
with fluorescence from the FLUO-4 probe determined at 485 nm excitation and
525 nm emission. Where specified, serotonin (20 mL) was added to a final
concentration of 1025 M.
Determination of cellular serotonin. For determinations in S. cerevisiae BY4743,
cells were transformed with plasmid pYES-TDC23, using the lithium acetate
method36. Transformant cells were cultured to OD600 , 2.0 in YNB broth with
appropriate selection37 before sub-culturing to fresh medium supplemented with or
without QN. Cells were harvested for analysis after 24 h incubation at 30uC. For
RN46A cells, these were seeded from confluent flasks (see above) to fresh medium
supplemented with QN or p-chlorophenylalanine (pCPA; Sigma) and incubated for
5 d at 36.5uC, 5% CO2. After harvesting by centrifugation, cells were suspended in
0.5 mL (yeast) or 1 mL of 0.1 M perchloric acid containing 1.6 mM sodium
metabisulphite. Cell lysis of yeast cells was facilitiated by mechanical breakage with
glass beads using a Fast Prep-24 MP bead beater. Cell lysates were centrifuged for
3 min at 15000 g at 4uC, and supernatants were stored at 280uC until analysis.
Protein was determined with a Bradford assay kit (BioRad). Serotonin was
determined using high performance liquid chromatography with electrochemical
detection (HPLC-ED) as previously described38. In brief, samples were thawed,
weighed and sonicated (Soniprep 150: MSE Scientific Instruments; Crawley, UK) for
30 s in 800 mL of 0.05 M perchloric acid containing 1 mM sodium metabisulphite,
then centrifuged (17,400 g, 4uC for 20 min; Harrier 18/80: MSE Scientific
Instruments; Crawley, UK) and the supernatant filtered (0.45 mm syringe tip filter,
Kinesis Ltd; St Neots, UK). Monoamines were separated using a PerkinElmer Series
200 autosampler and Targa C18 3 mm column (100 mm 3 2.1 mm: Presearch;
Basingstoke, UK) and detected at a potential of 10.59 V against ISAAC reference
electrode by an Antec Intro amperometric detector (Zoeterwoude, The Netherlands).
Mobile phase consisting of 20 mM potassium dihydrogen orthophosphate,
20 mM sodium acetate, 8 mM potassium chloride, 0.1 mM disodium
ethylenediaminetetraacetic acid (EDTA), 0.16 mM octanesulphonic acid and
10% v/v methanol adjusted to pH 3.8–4 was delivered at 0.2 mLmin21 by an isocratic
pump (Dionex P680) and quantification used Galaxie (version 1.8) software. (Antec).
The lower detection limit was 1 pmol per 20 mL sample.
Quinine uptake. S. cerevisiae BY4743 transformed with plasmid pYES-TDC, or
RN46A cells were cultured as described above. Media were supplemented with
0.1 mMQN, and [9-3H]-QN (American Radiolabeled Chemicals) to a final activity of
0.9 mCiml21 [10–20 Ci (mmol QN)21]. Where indicated, L-tryptophan was added to
a final concentration of 1 mM. After the same incubation times with QN as used
above for determination of cellular serotonin (24 h for yeast, 5 d for RN46A), cells
were washed and resuspended in phosphate buffered saline before splitting aliquots
for transfer to scintillation vials or retention for protein determination. Cell-
associated radioactivity was quantified in a liquid scintillation counter (2250CA
Packard Tri-carb) and the readings normalized to protein content, determined as
described above.
TPH2 activity.Apurified catalytic domain of human TPH224 was assayed for activity
as described previously24,39. The assay buffer comprised 200 mM ammonium
sulphate, 7 mM DTT, 25 mg mL21 catalase, 25 mM ferrous ammonium sulphate,
50 mMMES, pH 7.0, 150 mM 6-methyltetrahydropterin (6MePH4) (Sigma), 25 nM
TPH2 enzyme and 20 mM tryptophan.Where specified, tryptophan (0.02–0.25 mM)
or 6MePH4 (0.025–0.15 mM) concentrations were varied, and/or the assay buffer was
supplemented with QN. Enzyme activity was quantified with fluorescence
spectrophotometry (Cary Eclipse Varian) using a 4 mm quartz cuvette, 300 nm
excitation, 330 nm emission, with a 5 nm band pass.
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